| Date Checked | 2026-02-19 22:15:13 |
|---|
| Graham Number | (PB)nan vs (PE)0.00 |
|---|
| Over / Under Value Percentage | 0.00% vs 0.00% |
|---|
| Dividend Yield | 0.00% |
|---|
| Dividend Date | None |
|---|
| Symbol | GELS |
|---|
| AssetType | Common Stock |
|---|
| Name | Gelteq Limited Ordinary Shares |
|---|
| Description | Gelteq Limited (GELS) is a pioneering biotechnology company based in Caulfield, Australia, dedicated to creating and commercializing innovative gel-based drug delivery systems for both human and veterinary medical applications. By harnessing advanced technologies, Gelteq enhances the safety and effectiveness of therapeutic treatments, establishing itself as a significant contender in the biopharmaceutical sector. The company's strong emphasis on research and development underpins its commitment to improving patient outcomes and meeting critical unmet medical needs across various healthcare landscapes. |
|---|
| CIK | 0001920092 |
|---|
| Exchange | NASDAQ |
|---|
| Currency | USD |
|---|
| Country | USA |
|---|
| Sector | HEALTHCARE |
|---|
| Industry | DRUG MANUFACTURERS - SPECIALTY & GENERIC |
|---|
| Address | MONASH INNOVATION LABS, CLAYTON, VIC, AUSTRALIA, 3800 |
|---|
| OfficialSite | https://www.gelteq.com |
|---|
| FiscalYearEnd | June |
|---|
| LatestQuarter | 2024-09-30 |
|---|
| MarketCapitalization | 9254400 |
|---|
| EBITDA | -3843531 |
|---|
| PERatio | 0 |
|---|
| PEGRatio | None |
|---|
| BookValue | 1.059 |
|---|
| DividendPerShare | None |
|---|
| EPS | -0.48 |
|---|
| RevenuePerShareTTM | 0.045 |
|---|
| ProfitMargin | 0 |
|---|
| OperatingMarginTTM | -29.69 |
|---|
| ReturnOnAssetsTTM | -0.15 |
|---|
| ReturnOnEquityTTM | -0.43 |
|---|
| RevenueTTM | 413130 |
|---|
| GrossProfitTTM | 297740 |
|---|
| DilutedEPSTTM | -0.48 |
|---|
| QuarterlyEarningsGrowthYOY | 0 |
|---|
| QuarterlyRevenueGrowthYOY | 0.594 |
|---|
| AnalystTargetPrice | None |
|---|
| AnalystRatingStrongBuy | - |
|---|
| AnalystRatingBuy | - |
|---|
| AnalystRatingHold | - |
|---|
| AnalystRatingSell | - |
|---|
| AnalystRatingStrongSell | - |
|---|
| TrailingPE | - |
|---|
| ForwardPE | - |
|---|
| PriceToSalesRatioTTM | 22.4 |
|---|
| PriceToBookRatio | 0.871 |
|---|
| EVToRevenue | 106.5 |
|---|
| EVToEBITDA | - |
|---|
| Beta | None |
|---|
| 52WeekHigh | 4.11 |
|---|
| 52WeekLow | 0.77 |
|---|
| 50DayMovingAverage | 1.002 |
|---|
| 200DayMovingAverage | 1.401 |
|---|
| SharesOutstanding | 10711100 |
|---|
| SharesFloat | 5455600 |
|---|
| PercentInsiders | 47.527 |
|---|
| PercentInstitutions | 0.878 |
|---|
| ExDividendDate | None |
|---|
| dateChecked | 2026-02-19 22:15:13 |
|---|
| fresh | 1 |
|---|